FDA has accepted Karyopharm Therapeutics Inc.’s supplemental New Drug Application seeking approval for Xpovio—its first-in-class, oral selective inhibitor of nuclear export compound, as a new treatment for patients with multiple myeloma after at least one prior line of therapy.
The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.
